Gyre Therapeutics Inc GYRE 深 沪
等待开盘 05-22 09:30:00 美东时间
6.18
+0.140
+2.32%
华盛通- 最 高6.22
- 今 开6.04
- 成交量 9.74万股
- 最 低 5.97
- 昨 收 6.04
- 总市值 5.65亿
- 52周最高 9.42
- 市盈率 静 274.67
- 换手率 0.11%
- 52周最低 5.97
- 委 比 25.14%
- 总股本 9137.19万
- 历史最高 29271.2116
- 量 比 0.85
- 振 幅 4.14%
- 历史最低 -19.80
- 每 手 1
- 风险率 0.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gyre Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results.
Gyre Therapeutics shares are trading lower after the company reported worse-tha...
05-08 00:23
Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $137.033M Est
Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million to $100.500 million-$111.000 million vs $137.033 million estimate.
05-07 20:39
Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. The company reported quarterly sales of $22.519 million which missed
05-07 18:21
Gyre Therapeutics completes $300 million acquisition of Cullgen
Gyre Therapeutics completes $300 million acquisition of Cullgen Gyre Therapeutics completed acquisition of privately held Cullgen in an all-stock transaction valued at about USD 300 million, creating a U.S.- and China-based biopharmaceutical company. Cullgen became a wholly owned subsidiary; former
05-04 20:48
Gyre Therapeutics amends 8-K to correct Cullgen merger share conversion description
Gyre Therapeutics amends 8-K to correct Cullgen merger share conversion description Gyre Therapeutics filed an amended Form 8-K to correct a clerical error in its March 2, 2026 report describing how certain non-designated Cullgen stockholders’ shares convert in proposed merger. Revised disclosure cl
04-17 20:56
Gyre Therapeutics submits Hydronidone NDA to China NMPA for CHB-induced liver fibrosis
Gyre Therapeutics submits Hydronidone NDA to China NMPA for CHB-induced liver fibrosis Gyre said its majority indirectly owned subsidiary Gyre Pharmaceuticals submitted a New Drug Application to China’s National Medical Products Administration’s Center for Drug Evaluation for F351 (Hydronidone). The
03-23 19:51
BUZZ-U.S. STOCKS ON THE MOVE-Bumble, Dick's Sporting Goods
BUZZ-U.S. STOCKS ON THE MOVE-Bumble, Dick's Sporting Goods Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 12 (Reuters) - U.S. stock index futures fell on Thursday as oil p
03-12 19:52
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Gyre Therapeutics sees F351 liver fibrosis revenue potential of USD 400-600 million within five years
Gyre Therapeutics sees F351 liver fibrosis revenue potential of USD 400-600 million within five years Gyre said it sees potential liver fibrosis revenue of about USD 400-600 million within five years for Hydronidone (F351), based on patient population data. The company also said it expects ETUARY re
03-12 18:32
Gyre Therapeutics Sees FY2026 Sales $100.500M-$111.000M vs $146.133M Est
Gyre Therapeutics (NASDAQ:GYRE) sees FY2026 sales of $100.500 million-$111.000 million vs $146.133 million analyst estimate.
03-12 18:17
